FOXO4-DRI vs nearby senolytics Option FOXO4-DRI Type D-retro-inverso peptide Human trial stage None (preclinical only) Option Dasatinib + Quercetin (D+Q) Type Small-molecule drug + flavonoid Human trial stage Early human trials (e.g., Alzheimer's) Option Navitoclax Type BCL-2 family inhibitor Human trial stage Later-stage trials (e.g., myelofibrosis) D+Q and navitoclax are further along in humans but can affect healthy cells (e.g., low platelets)
8 Pharm Res (2010)Manning MC et al
If left untreated, they may develop into a more serious condition known as iron deficiency anemia (IDA) ( IDA is a condition in which your blood doesnt contain enough healthy, oxygen-carrying red blood cells
HBOT is not a replacement for emergency assessment, neurological care, or established concussion rehabilitation
Zhang HC, Yang YJ, Ma KX, Shi CY, Chen GW, Liu DZ
S.IgarashiP.KahnC